TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Subjective complaints of poor near vision that impact activities of daily living~Exclusion Criteria:~* History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery, radial keratotomy, or any intraocular surgery~* Use of any topical ophthalmic medications, including artificial tears other than the study medications during the study~* Use of temporary or permanent punctal plugs or history of punctal cautery in one or both eyes~* Corneal abnormalities (including keratoconus, corneal scar, Fuchs' endothelial dystrophy, guttata, or edema) in either eye that are likely to interfere with visual acuity~* Narrow iridocorneal angles (Shaffer grade ≤2 or lower on gonioscopy examination), history of angle-closure glaucoma, or previous iridotomy~* Diagnosis of any type of glaucoma or ocular hypertension

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Vehicle (Type: PLACEBO_COMPARATOR): Participants received one drop of vehicle in each eye, once daily, for up to 30 days.
- Pilocarpine HCl Ophthalmic Solution (Type: EXPERIMENTAL): Participants received one drop of pilocarpine HCl ophthalmic solution 1.25% in each eye, once daily, for up to 30 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ICD-9 code for asthma~* one or more outpatient pharmacy claims for fluticasone propionate 44mg or budesonide between January 1, 2000 and June 30, 2008~* ages 4 to 11 years~Exclusion Criteria:~* diagnosis of Cystic Fibrosis~* ≥ 1 Rx claim for any asthma controller in the pre-index period

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Children Ages 4-11 with asthma (Type: None): Children ages 4 to 11 with a diagnosis of asthma receiving a prescription for an asthma therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] Guidelines, 2007) and:~  1. Smoking history of at least 10 pack-years~ 2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) ≤ 65% and ≥ 30% of the predicted normal value~ 3. Post-bronchodilator FEV1/FVC (force vital capacity) \< 70%~Exclusion Criteria:~* Patients who have had a COPD exacerbation requiring systemic glucocorticosteroid treatment or antibiotics and/or hospitalization in the 6 weeks prior to screening or during the run-in period~* Patients who have had a respiratory tract infection within 6 weeks prior to screening or during the run-in period~* Patients with a body mass index less than 15 or more than 40 kg/m\^2~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular comorbid conditions~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 150 μg and tiotropium 18 μg (Type: EXPERIMENTAL): Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
- Tiotropium 18 μg (Type: ACTIVE_COMPARATOR): Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Mini-posterior Approach and Direct Anterior Approach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is willing and able to understand, sign and date the study specific Patient Informed Consent and Health Insurance Portability and Accountability Act (HIPPA) authorization to volunteer participation in the study.~* The subject is between 25 and 80 years of age at the time of surgery.~* The subject has elected to undergo primary total hip arthroplasty for osteoarthritis.~* The subject is psychosocially, mentally and physically able to comply with the requirements of the study including post-operative clinical, radiographic evaluations and completion of patient questionnaires.~* The subject is skeletally mature.~Exclusion Criteria:~* The subject has a BMI greater than 35.~* The subject has had a previous total hip arthroplasty.~* The subject has inflammatory arthritis.~* The subject has any type of infection.~* The subject has developmental dysplasia of the hip.~* The subject has a known metal allergy.~* The subject has an extreme offset of greater than 50 mm.~* The subject has an acetabular deformity requiring advanced reconstructive techniques.~* The subject has Charcot's disease.~* The subject has Paget's disease~* Dependence on narcotics for 6 months (or longer)

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Mini-Posterior Approach (Type: ACTIVE_COMPARATOR): Mini-Posterior surgical approach for total hip arthroplasty
- Direct Anterior Approach (Type: EXPERIMENTAL): Direct Anterior surgical approach for total hip arthroplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STRIPS: Shoulder Taping Reduces Injury and Pain in Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Stroke patients both ischemic and hemorrhagic with upper limb weakness within 48 hours after the ictus~2. Age over 18 years~3. Brunnstrom's stage of recovery 1 and 2~4. Patients willing to participate in the study~Exclusion Criteria:~1. Patients with Glasgow coma scale of \<7~2. Patients on ventilator~3. Uncooperative patients~4. Patients having previous history of shoulder injury~5. Patients with Wernicke's aphasia~6. Patients having previous history of shoulder pain~7. Any previous history of skin allergy to tape

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Taping (Type: EXPERIMENTAL): The tri-pull method of taping was used.Taping was initiated by first applying three, two-inch wide and approximately ten-inch long, pieces of elastic adhesive tape strips. The first strip was applied from the mid-humerus deltoid tuberosity across the scapula. The second strip was applied from the deltoid tuberosity across the clavicle to the mid-clavicle, but before the supra-sternal notch. The third strip was placed from the deltoid tuberosity over the acromion process to the neck.
- Sham Taping (Type: ACTIVE_COMPARATOR): This was done using the same tapes. Three strips of tapes were applied in same position without repositioning the joint. All other Physiotherapy measures like positioning, handling technique and range of motion exercises were equally done for both the groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adults 18-70 years of age;~* HBeAg-negative chronic hepatitis B for \>/=6 months;~* liver disease consistent with chronic hepatitis B.~Exclusion Criteria:~* interferon-based, systemic anti-HBV, antiviral, anti-neoplastic, or immunomodulatory therapy \</=12 months before first dose of study drug;~* non-responders to previous interferon therapy;~* co-infection with hepatitis A, C or D, or with human immunodeficiency virus (HIV);~* hepatocellular cancer;~* compensated (Child A, score 6) or decompensated liver disease (Child B or C).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PEG-IFN48 (Type: EXPERIMENTAL): Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks.
- PEG-IFN96 (Type: EXPERIMENTAL): Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by another 48 weeks of PEG-IFN treatment (total 96 weeks of treatment).
- PEG-IFN+LAM96 (Type: EXPERIMENTAL): Treatment with PEG-IFN and lamivudine in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by 48 weeks of only PEG-IFN treatment (total 96 weeks of treatment).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spinal Morphine in Robotic Assisted Radical Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for Robot-Assisted Radical Prostatectomy~Exclusion Criteria:~* Contra-indications to spinal anesthesia (severe aortic stenosis, coagulation disorders)~* Contra-indications to study medication (local anesthetics, morphine, paracetamol, metamizol)~* Conversion to an open procedure~* Post-operative ICU-admission

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: SHAM_COMPARATOR): subcutaneous lidocaïne and intravenous loading dose of morphine
- Intervention (Type: EXPERIMENTAL): Spinal injection of 4 or 5 ml of bupivacaine/morphine 2,5 mg/ml/60mcg/ml. The reduction to 4 ml is for patients over 75 years of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Ability of the TENA SmartCare Change Indicator to Reduce the Number of Manual Checks Between Changes of Absorbing Incontinence Products

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. DEU is diagnosed with urinary incontinence managed with a tape-style incontinence product.~2. DEU is unable to sufficiently communicate the need for an incontinence product to be changed.~3. DEU is being cared for in a home environment and most of the care is provided by a main CGR.~4. DEU is willing and able to provide informed consent and to participate in the clinical investigation or has a legally designated representative willing to provide informed consent on behalf of the DEU. Note, the legally designated representative and main CGR cannot be the same person.~5. CGR is willing and able to provide informed consent to participate in the clinical investigation.~6. The CGR frequently checks the saturation level of the incontinence product, manually and/or by a touch-feel process.~7. If incontinence is managed by pharmaceuticals, the dose regime is stable.~8. DEU and CGR ≥ 18 years of age.~Exclusion Criteria:~1. DEU is cared for in a professional establishment or is institutionalized.~2. DEU has ≥ 4 fecal incidences per week.~3. DEU has severe incontinence product related skin problems, as judged by the investigator.~4. DEU has any type of urinary catheter(s) resulting in improved/treated urinary incontinence.~5. The incontinence product is changed on a routine based on time (schedule) or device alert, without manual checks.~6. Any other condition that may make participation in the clinical investigation inappropriate, as judged by investigator.~7. CGR is incapable or unwilling to use the required smart phone application and/or the diary registration webpage required for the clinical investigation.~8. Participation in an investigational study of a drug, biologic, or device within 30 days prior to entering the clinical investigation or planned during the course of the clinical investigation.~9. DEU is pregnant or nursing.~10. CGR or DEU with an alcohol or drug addiction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational Device (Type: EXPERIMENTAL): TENA SmartCare Change Indicator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically\* confirmed adenocarcinoma of pancreas~  * Stage I-II disease~ * Resectable disease~* No superior mesenteric vein or artery, portal vein, celiac trunk, or hepatic artery infiltration~* No symptomatic duodenal stenosis~* NOTE: Patients without histological or cytological results may be allowed provided ≥ 1 attempt has been made by needle aspiration with negative imaging and clinical signs suggestive of adenocarcinoma.~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* WBC ≥ 3,500/mm³~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 10 g/dL~* Creatinine ≤ 1.5 mg/dL~* ALT and AST ≤ 3 times upper limit of normal~* Bilirubin ≤ 3 mg/dL~* No prior or concurrent malignancy within the past 5 years except for surgically cured carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin~* Not pregnant or nursing~* No psychological, familial, sociological, or geographical condition that would potentially hinder study compliance or follow-up schedule~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy for pancreatic adenocarcinoma~* No other concurrent experimental drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- adjuvant PEXG (Type: EXPERIMENTAL): cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 6 months
- perioperative PEXG (Type: EXPERIMENTAL): cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 3 months before surgery and 3 months after surgery
- Adjuvant Gemcitabine (Type: ACTIVE_COMPARATOR): Adjuvant Gemcitabine at 1000 mg/mq for 3 weeks every 4 weeks for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Diagnosed with FAB subtypes RA, RARS MDS (Low Risk)~OR~Diagnosed with AML and in complete remission within 5 years of treatment with less than 5 percent marrow blasts~OR~Diagnosed with CML In chronic phase~OR~Diagnosed with MDS, AML or CML and are between 6 months-3 years following allogeneic SCT who fulfill the following criteria:~100 percent donor engraftment,~less than 5 percent blasts in marrow~normal marrow cellularity~HLA-A0201 positive at one allele~Ages 18 - 85 years old~EXCLUSION CRITERIA:~Hypoplastic MDS~Relapsed AML~CML in accelerated phase or blast crisis~Relapsed MDS, AML or CML following hematopoietic stem cell transplantation~Hb less than 9 g/dl, neutrophil count less than 1 times 10(9)/1, and/ or platelet count less than 75 times 10(9)/1~Hypocellular bone marrow~History of Wegener's granulomatosis~Serologic antibody against proteinase-3 (ANCA positive)~Previous allergic reaction to montanide adjuvant~Positive test for HIV~Treatment with systemic corticosteroids within 14 days prior to study entry~Co-morbidity of such severity that it would preclude the subject's ability to tolerate protocol therapy~Predicted survival less than 28 days~Pregnant or breast feeding (All female subjects must have a urine pregnancy test within 1 week prior to vaccine administration)~Enrolled in another drug or vaccine clinical trial during the study period~Inability to comprehend the investigational nature of the study and provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Lean cohort~1. Men and women\>18 years of age;~2. Normal body weight (18.5 ≤ BMI ≤25 kg/m2);~3. T2D patients can be on treatment with oral glucose lowering therapies, and if they are, they must have been on these treatments for at least 12 weeks prior to screening;~4. 6.5≤HBA1c≤10% at screening;~5. Agreement to maintain prior diet and exercise habits for the duration of the study.~Overweight cohort~1. Men and women\>18 years of age;~2. Increased body weight (BMI \>27 kg/m2);~3. T2D patients can be on treatment with oral glucose lowering therapies, and must have been on these treatments for at least 12 weeks prior to screening;~4. 6.5≤HBA1c≤10% at screening;~5. Agreement to maintain prior diet and exercise habits for the duration of the study.~Exclusion Criteria:~1. Any type of diabetes other than T2D;~2. Past history of significant CAD;~3. Known HF;~4. Significant renal impairment (eGFR\<30ml/min/m2);~5. Participation in a clinical trial of an investigational medicinal product (CTIMP) in the preceding 12 weeks;~6. Known hypersensitivity to dobutamine or gadolinium or any other contra-indications to MRI;~7. Participants with obesity where their girth exceeds the scanner bore;~8. History of pancreatitis;~9. Any history of liver disease;~10. Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2);~11. Prior or current use of thiazolidinediones (aka PPAR-γ agonists), fibrates, GLP-1RA or insulin;~12. Patients that are pregnant (female participants only);~13. Inflammatory bowel disease~14. Diabetic gastroparesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide-Pioglitazone (Type: ACTIVE_COMPARATOR): Participants randomised to receive liraglutide treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with pioglitazone.
- Pioglitazone-Liraglutide (Type: ACTIVE_COMPARATOR): Participants randomised to receive pioglitazone treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with liraglutide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete